Compare ALMU & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALMU | CYRX |
|---|---|---|
| Founded | 2019 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.6M | 472.7M |
| IPO Year | N/A | N/A |
| Metric | ALMU | CYRX |
|---|---|---|
| Price | $18.55 | $11.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $25.50 | $12.83 |
| AVG Volume (30 Days) | ★ 435.8K | 344.0K |
| Earning Date | 02-07-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.27 |
| Revenue | $5,569,000.00 | ★ $243,795,000.00 |
| Revenue This Year | $20.26 | N/A |
| Revenue Next Year | $69.09 | $9.27 |
| P/E Ratio | ★ N/A | $8.69 |
| Revenue Growth | ★ 307.21 | 41.27 |
| 52 Week Low | $5.69 | $4.58 |
| 52 Week High | $25.88 | $11.44 |
| Indicator | ALMU | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.41 | 67.43 |
| Support Level | $18.00 | $10.39 |
| Resistance Level | $23.37 | $11.38 |
| Average True Range (ATR) | 1.92 | 0.45 |
| MACD | -0.31 | 0.06 |
| Stochastic Oscillator | 28.85 | 90.21 |
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.